← Eichor · All briefs

NCT02231008 — Smith-Magenis Syndrome trial site landscape

Public-registry site landscape for NCT02231008, a Smith-Magenis Syndrome study sponsored by Vanda Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.

TrialNCT02231008 (registry record)
SponsorVanda Pharmaceuticals
Condition(s)Smith-Magenis Syndrome; Circadian
PhasePHASE2 / PHASE3
Listed sites4
Site countriesUnited States

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT02231008 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →
Launch offer through July 31: first full site unlock free — one per company.